For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the arrival of Vyndamax and Attruby represents a significant advancement . These innovative therapies stabilize the transthyretin protein, preventing its destructive build-up and reducing the burden of the condition . Patients are now experiencing impro